/
NTLA
$16.54-$0.14 (-0.87%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$2.3B
140M shares
52-week range
$7.95 – $28.25
42% from low
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Exchange
NASDAQ
CS
Borrow rate
0.29%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-145.38
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $30.4M | $43.1M | $58.0M | $33.1M | $52.1M | $36.3M | $57.9M | $67.7M |
| Cost of revenue | $89.1M | $108.4M | $150.4M | $6.9M | $7.6M | $9.0M | $10.3M | $15.9M |
| Gross profit | −$58.7M | −$65.3M | −$92.4M | $26.2M | $44.5M | $27.3M | $47.6M | $51.7M |
| Gross margin | -192.8% | -151.5% | -159.4% | 79.2% | 85.5% | 75.3% | 82.2% | 76.5% |
| R&D | $89.1M | $108.4M | $150.4M | $229.8M | $420.0M | $435.1M | $466.3M | $388.9M |
| Operating income | −$90.9M | −$106.4M | −$136.6M | −$267.9M | −$458.2M | −$515.3M | −$534.3M | −$441.0M |
| EBITDA | −$86.4M | −$100.8M | −$130.3M | −$261.0M | −$466.6M | −$472.2M | −$508.7M | −$396.8M |
| Net income | −$85.3M | −$99.5M | −$134.2M | −$267.9M | −$474.2M | −$481.2M | −$519.0M | −$412.7M |
| Net margin | -280.4% | -230.9% | -231.5% | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| EPS (diluted) | -1.98 | -1.96 | -2.40 | -3.78 | -6.16 | -5.42 | -5.25 | -3.81 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $59M | $-3.22 | $-3.59–$-2.79 | 15 |
| 2027 | $269M | $-1.85 | $-8.85–$36.85 | 15 |
| 2028 | $661M | $-0.67 | $-12.74–$55.33 | 10 |
| 2029 | $1.7B | $4.11 | $-1.01–$36.38 | 4 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Intellia Therapeutics, Inc
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
www.intelliatx.com- Employees
- 377
- IPO / List date
- May 6, 2016
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds NTLA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 1,672,700 | $15.0M |
| Bridgewater Associatesas of 2025-12-31 | 223,166 | $2.0M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NTLA yet.
